P2X7 receptor pharmacological inhibitor SGM-1019 was shown to block IL-1β secretion in KCs, HSC activation, and collagen deposition in human cells from NASH and in the primate model from CCl4-induced liver fibrosis (134). This evidence concerns the gene IL1B and metabolic dysfunction-associated steatohepatitis.